Quick Answer
Clearside Biomedical, Inc. reported Long-Term Debt of $3.82 million for fiscal year 2019.
Clearside Biomedical, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2019 | $3.82M | -59.5% |
| 2018 | $9.42M | +95.9% |
| 2017 | $4.81M | -36.6% |
| 2016 | $7.59M | +78.8% |
| 2015 | $4.24M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2020 | $385.0K | -91.1% | -22.4% |
| June 30, 2020 | $496.0K | -93.7% | -87.0% |
| December 31, 2019 | $3.82M | -59.5% | -11.8% |
| September 30, 2019 | $4.33M | -56.3% | -45.0% |
| June 30, 2019 | $7.88M | -20.0% | -8.9% |
| March 31, 2019 | $8.65M | +110.5% | -8.2% |
| December 31, 2018 | $9.42M | +95.9% | -5.0% |
| September 30, 2018 | $9.91M | +80.1% | +0.6% |
- Clearside Biomedical, Inc. showed a decrease of -59.5% in Long-Term Debt compared to the prior fiscal year.
- Over the 2015–2019 period, Clearside Biomedical, Inc.’s long-term debt has declined by 10.0% (from $4.24 million to $3.82 million).
- The most recent figure is from Clearside Biomedical, Inc.’s fiscal year 2020 report (Form 10-K), filed with the SEC on March 15, 2021.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: